ZBIO catalyst calendar

Zenas BioPharma, Inc.

Upcoming catalysts
2
Cash runway
25.7 months
Cash & investments
$643M
Phase 3 programs
4

Zenas BioPharma, Inc. is tracked here for clinical trial milestones, SEC filings and earnings dates. Focus area: Pharmaceutical Preparations.

The next scheduled catalyst is A Study of Orelabrutinib in Patients With Primary Progressive Multiple Sclerosis on June 15, 2030. There are 2 upcoming events on record.

Cash runway is approximately 25.7 months based on the most recent reported cash position and quarterly operating burn as of 2026-06-30.

Upcoming catalysts

DateEventTypePhase
June 15, 2030 A Study of Orelabrutinib in Patients With Primary Progressive Multiple Sclerosis Trial Milestone Phase 3
June 15, 2030 A Study of Orelabrutinib in Patients With Secondary Progressive Multiple Sclerosis Trial Milestone Phase 3

Track ZBIO alongside other companies. Add it to a watchlist and see every catalyst on one calendar.

Open ZBIO in the tracker

Recent history

DateEventTypePhase
October 13, 2026 8-K filed: Reg FD disclosure Filing —
September 15, 2026 A Study of Obexelimab in Patients With Systemic Lupus Erythematosus Trial Milestone Phase 2
August 13, 2026 Quarterly results filed (8-K) Earnings —
June 30, 2026 A Study of Obexelimab in Patients With Warm Autoimmune Hemolytic Anemia (SApHiAre) Trial Milestone Phase 3
May 13, 2026 Quarterly results filed (8-K) Earnings —
March 31, 2026 8-K filed: Material agreement, Other event Corporate —
March 16, 2026 Quarterly results filed (8-K) Earnings —
February 16, 2026 A Study to Evaluate Safety and Pharmacokinetics of ZB002 in Healthy Participants and Participants With Rheumatoid Arthritis Trial Milestone Phase 1
February 13, 2026 8-K filed: Leadership change Corporate —
January 5, 2026 Quarterly results filed (8-K) Earnings —
December 15, 2025 8-K filed: Leadership change Corporate —
November 13, 2025 A Phase 3 Study of Obexelimab in Patients With IgG4-Related Disease Trial Milestone Phase 3
November 12, 2025 Quarterly results filed (8-K) Earnings —
October 27, 2025 8-K filed: Reg FD disclosure, Other event Filing —
October 8, 2025 Quarterly results filed (8-K) Earnings —
September 2, 2025 8-K filed: Material agreement, Acquisition completed, Reg FD disclosure Corporate —
August 28, 2025 A Study of Obexelimab in Patients With Relapsing Multiple Sclerosis (MoonStone) Trial Milestone Phase 2
August 12, 2025 Quarterly results filed (8-K) Earnings —
June 12, 2025 8-K filed: Leadership change Corporate —
June 4, 2025 8-K filed: Reg FD disclosure Filing —
May 15, 2025 Quarterly results filed (8-K) Earnings —
April 17, 2024 Study of ZB001 in Chinese Patients With Thyroid Eye Disease Trial Milestone Phase 1
March 21, 2024 A Safety and Pharmacokinetics Study of ZB004 in Healthy Participants Trial Milestone Phase 1
April 4, 2023 A Safety, Tolerability and Pharmacokinetics Study of ZB001 in Healthy Subjects Trial Milestone Phase 1

About this data

Trial milestones come from the ClinicalTrials.gov v2 API, filings from SEC EDGAR, and financial figures from SEC XBRL company facts. Dates marked est. are projected rather than company-confirmed. This is an information tool, not investment advice — verify anything you act on against the linked primary source.

Last updated 2026-10-14.